Eupraxia Pharmaceuticals Inc.
EPRX
$3.10
-$0.17-5.20%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 61.90% | -13.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.26% | -4.30% | |||
| Operating Income | -19.26% | 4.30% | |||
| Income Before Tax | -25.69% | 1.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.72% | 1.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -51.25% | -15.34% | |||
| Net Income | -26.34% | 1.06% | |||
| EBIT | -19.26% | 4.30% | |||
| EBITDA | -137.27% | 4.33% | |||
| EPS Basic | -159.77% | 1.07% | |||
| Normalized Basic EPS | -26.69% | 1.24% | |||
| EPS Diluted | -164.57% | 1.07% | |||
| Normalized Diluted EPS | -26.69% | 1.24% | |||
| Average Basic Shares Outstanding | 0.05% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
